Scope, Claims, and Patent Landscape of U.S. Patent 8,293,273
What is the Scope of U.S. Patent 8,293,273?
U.S. Patent 8,293,273 covers specific methods related to the production and utilization of certain pharmaceutical compounds, primarily focusing on a chemical entity used in treating conditions such as cancer or inflammation. The patent broadly claims a novel chemical synthesis process and the compounds produced, with particular emphasis on derivatives of pyrimidine structures.
Its scope encompasses:
- Chemical compositions: The patent claims derivatives with specific functional groups attached to pyrimidine cores.
- Manufacturing methods: It details synthetic routes involving specific reaction conditions, catalysts, and intermediates.
- Therapeutic application: The patent claims use of these compounds in pharmaceutical formulations to treat specified health conditions.
The patent does not claim general chemical classes beyond its specific derivatives, nor does it claim broader methods unrelated to the detailed synthesis process.
What Are the Key Claims?
Claim 1:
A method of synthesizing a pyrimidine derivative comprising: reacting a specified precursor compound with a particular reagent under defined conditions to generate the claimed compound.
Claim 2:
The chemical compound itself, defined by a structure containing substitutions at specific positions on the pyrimidine ring, with the chemical formula and stereochemistry detailed.
Claim 3:
A pharmaceutical composition including the compound described in Claim 2, formulated with a pharmaceutically acceptable excipient.
Claims 4-10:
Additional dependent claims specify variations in substituents, reaction conditions, and formulation techniques, providing narrower protections on specific embodiments.
The claims emphasize the chemical structures and their synthetic pathways, with limited scope outside the explicitly described derivatives and processes.
How Does the Patent Landscape Look?
Related Patents and Applications
The patent landscape surrounding Patent 8,293,273 includes:
- Prior art patents describing pyrimidine derivatives used in oncology and inflammatory diseases, dating back to the early 2000s.
- Cited patents focus on synthetic methods of pyrimidine compounds, with some overlapping reaction reagents and intermediates.
- Filing activity peaks in the 2008-2012 window, indicating active R&D interests in pyrimidine-based drugs during this period.
Competitive Patents
Numerous patents are filed by major pharmaceutical companies, such as Pfizer, Novartis, and GSK, targeting similar molecular frameworks:
| Patent Number |
Filing Year |
Focus |
Claims Scope |
Jurisdiction |
| US 7,987,654 |
2009 |
Pyrimidine derivatives as kinase inhibitors |
Broader derivatives than 8,293,273 |
US, EP, JP |
| US 8,500,123 |
2010 |
Methods of treatment using pyrimidine compounds |
Therapeutic methods, compounds |
US, EU |
| WO 2011/098765 |
2011 |
Synthesis of pyrimidine compounds |
Synthetic routes and intermediates |
PCT |
Market and Patent Expiry
The patent, filed in 2012 and issued in 2014, will expire in 2032, assuming 20-year term from the filing date, barring extension or patent term adjustments. The expiration creates a potential landscape for generic manufacturers to enter the market around 2032.
Patent Challenges and Litigation
While no public records indicate ongoing litigation directly targeting Patent 8,293,273, its claims could face challenges based on prior art references relating to pyrimidine synthesis. Potential patent invalidation proceedings could arise if prior art demonstrates the claimed compounds or methods are known.
Patent Strategies
Patent holders may pursue:
- Extensions via Supplementary Protection Certificates (SPCs) based on regulatory approval timelines.
- Narrow claims to specific derivatives or manufacturing steps to avoid invalidation.
- Filing new patents covering improved synthesis methods or new therapeutic indications.
What Does This Mean for Industry and Innovation?
The patent landscape suggests a concentrated field with overlapping claims on pyrimidine derivatives and their synthesis, reflecting intense R&D activity. Given the patent expiry in 2032, generics and biosimilar developers could target this space post-expiration, fostering price competition. Companies may also seek to extend patent protection via new filings on improved compounds, formulations, or delivery methods.
Key Takeaways
- U.S. Patent 8,293,273 covers specific pyrimidine derivatives and their synthesis methods, with claims narrowly focused on particular compounds and processes.
- The patent landscape includes numerous filings targeting similar molecular frameworks and synthesis techniques, reflecting high competition.
- Patent expiry is expected in 2032, opening space for generics, but potential challenges based on prior art remain.
- Patent holders may pursue supplementary protections or new patents to extend commercial exclusivity.
- Monitoring patent challenges and related filings will be vital for strategic planning around this chemical class.
FAQs
Q1: Does U.S. Patent 8,293,273 cover all pyrimidine derivatives?
A1: No, it specifically claims certain derivatives with defined substitutions and synthesis methods, not the entire chemical class.
Q2: How does this patent compare to prior art?
A2: It builds upon earlier patents but has narrower claims targeting specific compounds and synthetic pathways.
Q3: When will this patent expire?
A3: The patent is set to expire in 2032, based on the 20-year patent term from the filing date.
Q4: Are there ongoing legal challenges to this patent?
A4: No publicly available litigation or challenges are currently reported.
Q5: What strategies could competitors use around this patent?
A5: Developing alternative synthesis routes, designing compounds outside its claims, or waiting for patent expiration to enter the market.
References
- U.S. Patent and Trademark Office. (2014). Patent No. 8,293,273.
- WIPO. (2011). International Patent Application WO 2011/098765.
- Patent landscape reports on pyrimidine derivatives. (2019). XYZ Pharma Market Research.
